medimmune inc earnings forecast raised amid higher sales medimmune inc expects to report that its first quarter earnings surged from a year earlier excluding stock based compensation expenses due in part to stronger sales of its respiratory therapy drug synagis the gaithersburg md drug maker said it estimates first quarter earnings excluding the stock based compensation expenses of cents to cents a share compared with cents a share excluding the same expenses a year earlier medimmune reported net income of &# million or cents a share for last years first period the company said it expects to report that revenue grew to from &# million a year earlier with sales of synagis increasing to last year first quarter sales fell as synagis sales slipped to &# million 
